ELMMB logo
Facebook logo Twitter logo


The National Patient Safety Agency (NPSA) has published guidance for NHS and independent healthcare organisations to improve the safety of lithium therapy.

It is recommended that patients who are prescribed lithium are monitored in accordance with the National Institute for Clinical Excellence (NICE) guidelines. These stipulate that lithium blood levels should be assessed every three months, while thyroid and renal function tests should be undertaken every six months.

Patients beginning treatment with Lithium under the direction of hospital services will be transferred to the care of their own doctor in the community and the following booklets and alert cards are availble for the patient to ensure that safer lithium therapy is maintained.